While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the sustainability of a trend isn't easy. The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock ali ...

If approved, neffy 1 mg will be the first and only needle-free epinephrine treatment available for younger school-aged children The submission of neffy 1 mg sNDA follows FDA approval on August 9, 2024, of neffy (2 mg) for the treatment of Type I Allergic Reactions, including anaphylaxis, in adults and children who weigh 30 kg (66 lbs.) or greater SAN DIEGO, Sept. 09, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and th ...

ARS Pharmaceuticals, Inc. (SPRY) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years. Ind ...

vgajic/E+ via Getty Images Investment Overview The San Diego based biotech ARS Pharmaceutical's (NASDAQ:SPRY) share price is up nearly 120% year-to-date, and at the end of August, shares made a quick >20% gain, after its lead and only product, neffy, a nasal spray, was approved for commercial use by the FDA, ahead of schedule, for the treatment of Type I Allergic Reactions. In its latest, Q2 2024 quarterly report / 10Q submission, ARS provides basic information around neffy as follows: ARS-1 (brand name nef ...

EURneffy offers adults and children (≥30 kg) in Europe living with severe allergic reactions the first new delivery method for adrenaline in more than 30 years in the EU European Commission decision follows FDA approval in the United States on August 9, 2024 SAN DIEGO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to the development of products to better protect patients from severe allergic reactions that could lead to anaphylaxis, announc ...

Earlier this month, the FDA approved ARS Pharmaceuticals Inc's SPRY neffy (epinephrine nasal spray) for the emergency treatment of allergic reactions (Type I), including those that are life-threatening (anaphylaxis), for adult and pediatric patients. ARS Pharma's Neffy is to be an alternative to EpiPen and other autoinjectors like Sanofi SA's SNY Auvi-Q filled with epinephrine. Also Read: Allergic Reaction Focused ARS Pharmaceuticals' Lead Candidate Shows Efficacy In Skin Disorder. Cantor Fitzgerald initiat ...

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) ARS Pharmaceuticals neffy (epinephrine nasal spray) FDA Approval Conference Call August 12, 2024 8:00 AM ET Company Participants Justin Chakma - Chief Business Officer Richard Lowenthal - President and CEO Eric Karas - Chief Commercial Officer Conference Call Participants Tim Lugo - William Blair Ryan Deschner - Raymond James Roanna Ruiz - Leerink Partners Julian Harrison - BTIG Operator Good day and welcome to the ARS Pharmaceuticals' neffy (epinephrine nasal spray) ...

ARS Update neffy® Approval August 12, 2024 | --- ...

neffy Offers Adults and Children (≥30 kg) Living with Severe Allergic Reactions the First New Delivery Method for Epinephrine in more than 35 Years Well-capitalized to Support Launch and Commercialization of neffy in the U.S., and an Expected Operating Runway of at Least Three Years ARS Pharma to Host Investor Conference Call on Monday, August 12, 2024, at 8:00 am ET SAN DIEGO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at- ...

SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced its participation in the 2024 Wedbush PacGrow Healthcare Conference being held August 13-14, 2024 in New York City. Company management will participate in one-on-one meetings with investors on Wednesday, August 14, 2024. About ARS Pha ...